A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (RAINBOW)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01170663
First received: July 21, 2010
Last updated: July 1, 2014
Last verified: July 2014
  Purpose

This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.


Condition Intervention Phase
Gastric Cancer
Biological: Ramucirumab (IMC-1211B) DP
Drug: Placebo
Drug: Paclitaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Overall Survival Time (OS) [ Time Frame: Randomization up to 27.5 months ] [ Designated as safety issue: No ]
    OS time was measured from date of randomization to date of death from any cause. Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive.


Secondary Outcome Measures:
  • Progression-Free Survival (PFS) [ Time Frame: Randomization up to 22.2 months ] [ Designated as safety issue: No ]
    PFS was measured from date of randomization to first radiographically documented progressive disease (PD) or death due to any cause. PD defined using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Participants who had no baseline or post baseline radiological tumor assessment were censored at date of randomization. Participants who had no tumor progression or death within 2 scan intervals following the last assessment were censored at the date of last radiographic tumor assessment. Participants who began new anticancer treatment and had no tumor progression were censored at date of assessment prior to initiation of new therapy. Participants lost to follow-up or withdrew consent were censored at the date of their last assessment.

  • Time to Progressive Disease (TTP) [ Time Frame: Baseline up to 22.2 months ] [ Designated as safety issue: No ]
    TTP was defined as the time from randomization until date of radiographic progression using RECIST v1.1 criteria. PD was defined as having a ≥20% increase in sum of longest diameter (LD) of target lesions and at minimum 5 millimeters (mm) increase above nadir. Participants who did not progress or were lost to follow-up were censored at the date of last tumor assessment. Participants who had no baseline tumor assessment or no post baseline assessment and no death reported with 2 scan intervals post randomization were censored at date of randomization. Participants with no progression and not died within 2 scan intervals after last assessment were censored at date of last tumor assessment. Participants with no post baseline assessment or tumor progression but death reported within 2 scan intervals after randomization were censored at date of death.

  • Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or PD [ Time Frame: Randomization up to 22.2 months ] [ Designated as safety issue: No ]
    BOR was defined as the best response across all time points from randomization until radiologically confirmed PD using RECIST, v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. PD was defined as having a ≥20% increase in sum of LD of target lesions and ≥5 mm increase above nadir. SD was defined as small changes that did not meet above criteria.

  • Percentage of Participants With CR or PR [Objective Response Rate (ORR)] [ Time Frame: Randomization up to 22.2 months ] [ Designated as safety issue: No ]
    ORR was the percentage of participants who had CR or PR defined using RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. Percentage of participants calculated as: (number of participants with CR + PR)/(total number of participants)*100.

  • Percentage of Participants With Anti-Ramucirumab Antibodies (Serum Anti-Ramucirumab Antibody Assessment )(Immunogenicity) [ Time Frame: Prior to and after ramucirumab (IMC-1121B) infusion: Day 1 Cycles 1, 2 and 3 (28-day cycles) Doses 1, 4, 7 and 30-37 days after last dose of study therapy up to 103 weeks ] [ Designated as safety issue: No ]
    Participants who developed treatment-emergent antibody responses to Ramucirumab (IMC-1121B) after baseline.

  • Maximum Concentration (Cmax) After First Ramucirumab (IMC-1211B) Infusion [ Time Frame: Cycle 1, Day 1, 1 hour post end of infusion (28-day cycles) ] [ Designated as safety issue: No ]
  • Cmax After 4th Ramucirumab (IMC-1211B) Infusion [ Time Frame: Cycle 2, Day 15 1 hour post end of infusion (28-day cycles) ] [ Designated as safety issue: No ]
  • Cmax After 7th Ramucirumab (IMC-1211B) Infusion [ Time Frame: Cycle 4, Day 1, 1 hour post end of infusion (28-day cycles) ] [ Designated as safety issue: No ]
  • Minimum Concentration (Cmin) Prior to First Ramucirumab (IMC-1211B) Infusion [ Time Frame: Cycle 1, Day 1 predose (28-day cycles) ] [ Designated as safety issue: No ]
    This outcome measure was included in error as the time point was before ramucirumab (IMC-1211B) was administered. Cmin was not analyzed.

  • Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion [ Time Frame: Cycle 2, Day 15 (28-day cycle) ] [ Designated as safety issue: No ]
  • Cmin Prior to 7th Ramucirumab (IMC-1211B) Infusion [ Time Frame: Cycle 4, Day 1 (28-day cycles) ] [ Designated as safety issue: No ]
  • Change From Baseline to End of Therapy in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life: Questionnaire (QLQ-C30) in Global Health Status [ Time Frame: Baseline, end of therapy (up to 103 weeks) ] [ Designated as safety issue: No ]
    EORTC QLQ-C30 v3.0 is a 30-item, self-administered questionnaire with multidimensional scales assessing 15 domains (5 functional domains [physical, role, cognitive, emotional, and social], 9 symptom scales [fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties] and global health status scale). 28 questions assessed on a 1 (not at all) to 4 (very much) scale and the remaining 2 questions used a 1 (poor) to 7 (excellent) scale. A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.

  • Change From Baseline to End of Therapy in European Quality of Life Questionnaire-5 Dimension (EuroQol EQ-5D) Index Score [ Time Frame: Baseline, end of therapy (up to 103 weeks) ] [ Designated as safety issue: No ]
    The EQ-5D is a generic, multidimensional, health status instrument. The profile allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale [1 (no problem), 2 (some problems), and 3 (major problems)]. These combinations of responses were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status.


Other Outcome Measures:
  • Number of Participants With Serious and Other Non-serious Adverse Events (AE) and Who Died [ Time Frame: Baseline up to 103 weeks and within 30 days of last dose of study drug ] [ Designated as safety issue: Yes ]
    Participants who died or who had clinically significant events defined as serious AEs (SAEs) and other non-serious AEs (regardless of causality). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.


Enrollment: 665
Study Start Date: December 2010
Estimated Study Completion Date: September 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
Ramucirumab (IMC-1211B) DP and Paclitaxel
Biological: Ramucirumab (IMC-1211B) DP
8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
Other Names:
  • LY3009806
  • IMC-1211B
Drug: Paclitaxel
Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
Placebo Comparator: Placebo and Paclitaxel
Placebo and Paclitaxel
Drug: Placebo
Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
Drug: Paclitaxel
Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle

Detailed Description:

The aim of this study is to determine if paclitaxel given together with ramucirumab (IMC-1211B) as second line therapy will prolong overall survival (OS) compared to paclitaxel alone.

Approximately 663 participants (at least 18 years) in approximately 200 study centers and in approximately 30 countries will be randomized with histologically or cytologically confirmed metastatic gastric or gastroesophageal junction adenocarcinoma. Participants must have received at least one cycle of first line therapy with any platinum/fluoropyrimidine doublet with or without anthracycline (epirubicin or doxorubicin) and must have discontinued this therapy prior to study entry due to disease progression.

Upon registration and completion of screening procedure and reviewing the Inclusion and Exclusion Criteria eligible participants will be randomized to receive either paclitaxel plus ramucirumab or paclitaxel plus placebo.

Ramucirumab (IMC-1211B) DP/placebo will be administered IV on Days 1 and 15, paclitaxel will be administered IV on Days 1, 8 and 15 of a 4 weekly cycle.

Participants will be continuously treated and monitored until radiographic or symptomatic progression of disease, toxicity requiring cessation, protocol noncompliance, or withdrawal of consent.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent
  • histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma
  • Metastatic disease or locally advanced, unresectable disease
  • Disease progression during or within 4 months after the last dose of the first-line therapy (platinum/fluoropyrimidine doublet with or without anthracycline)
  • Organs are functioning well (liver, kidney, blood)
  • Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1

Exclusion Criteria:

  • First line chemotherapy for metastatic gastric cancer other than platinum/fluoropyrimidine doublet with or without anthracycline
  • Previous systemic therapy with other anti-angiogenic drugs
  • Uncontrolled high blood pressure
  • Symptomatic or poorly controlled heart disease or had a heart attack or stroke within the last 6 month
  • Evidence of central nervous system (CNS) metastasis at baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01170663

  Hide Study Locations
Locations
United States, California
ImClone Investigational Site
Burbank, California, United States, 91505
ImClone Investigational Site
Los Angeles, California, United States, 90095
ImClone Investigational Site
San Francisco, California, United States, 94115
United States, Florida
ImClone Investigational Site
Jacksonville, Florida, United States, 32207
ImClone Investigational Site
Miramar, Florida, United States, 33027
United States, Georgia
ImClone Investigational Site
Atlanta, Georgia, United States, 30322
United States, Hawaii
ImClone Investigational Site
Honolulu, Hawaii, United States, 96813
United States, New Jersey
ImClone Investigational Site
East Orange, New Jersey, United States, 07018
United States, New Mexico
ImClone Investigational Site
Albuquerque, New Mexico, United States, 87131
United States, New York
ImClone Investigational Site
New York, New York, United States, 10016
United States, Tennessee
ImClone Investigational Site
Chattanooga, Tennessee, United States, 37404
United States, Texas
ImClone Investigational Site
Houston, Texas, United States, 77030
United States, Washington
ImClone Investigational Site
Seattle, Washington, United States, 98109
Argentina
ImClone Investigational Site
Buenos Aires, Argentina, C1019ABS
ImClone Investigational Site
Caba, Argentina, C1050AAK
ImClone Investigational Site
Rosario, Argentina, 2000
ImClone Investigational Site
Santa Fe, Argentina, 3000
Australia, New South Wales
ImClone Investigational Site
Bankstown, New South Wales, Australia, 2200
ImClone Investigational Site
Kogarah, New South Wales, Australia, 2217
ImClone Investigational Site
Liverpool, New South Wales, Australia, 2170
ImClone Investigational Site
Wollongong, New South Wales, Australia, 2500
Australia, Queensland
ImClone Investigational Site
Southport, Queensland, Australia, 4215
Australia, South Australia
ImClone Investigational Site
Kurralta Park, South Australia, Australia, 5037
Australia, Victoria
ImClone Investigational Site
Coburg, Victoria, Australia, 3058
ImClone Investigational Site
Footscray, Victoria, Australia, 3011
ImClone Investigational Site
Frankston, Victoria, Australia, 3199
ImClone Investigational Site
Parkville, Victoria, Australia, 3050
Austria
ImClone Investigational Site
Graz, Austria, 8036
ImClone Investigational Site
Linz, Austria, A-4010
ImClone Investigational Site
Steyr, Austria, 4400
ImClone Investigational Site
Vienna, Austria, 1100
Belgium
ImClone Investigational Site
Bonheiden, Belgium, 2820
ImClone Investigational Site
Brugge, Belgium, 8310
ImClone Investigational Site
Brussels, Belgium, 1070
ImClone Investigational Site
Brussels, Belgium, 1000
ImClone Investigational Site
Edegem, Belgium, 2650
ImClone Investigational Site
Leuven, Belgium, 3000
Brazil
ImClone Investigational Site
Belo Horizonte, Brazil, 30130-100
ImClone Investigational Site
Belo Horizonte, Brazil, 30150-281
ImClone Investigational Site
Caxias Do Sul, Brazil, 95070560
ImClone Investigational Site
Dois Lajeados, Brazil, 95900-000
ImClone Investigational Site
Gavea, Brazil, 22451-010
ImClone Investigational Site
Ijui, Brazil, 98700 000
ImClone Investigational Site
Itajai, Brazil, 88301-170
ImClone Investigational Site
Londrina, Brazil, 86050-190
ImClone Investigational Site
Passo Fundo, Brazil, 99010-260
ImClone Investigational Site
Porto Alegre, Brazil, 90035-903
ImClone Investigational Site
Porto Alegre-Rs, Brazil, 90020090
ImClone Investigational Site
Ribeirão Preto, Brazil, 14015-130
ImClone Investigational Site
Rio De Janeiro, Brazil, 20231-050
ImClone Investigational Site
Salvador, Brazil, 41820-021
ImClone Investigational Site
Sao Jose Rio Preto, Brazil, 15090-000
ImClone Investigational Site
Sorocaba, Brazil, 18031-000
ImClone Investigational Site
São Paulo, Brazil, 04122-000
ImClone Investigational Site
São Paulo, Brazil, 01246-000
ImClone Investigational Site
São Paulo, Brazil
Bulgaria
ImClone Investigational Site
Sofia, Bulgaria, 1756
ImClone Investigational Site
Varna, Bulgaria, 9000
Chile
ImClone Investigational Site
Providencia, Chile
ImClone Investigational Site
Vina Del Mar, Chile
Estonia
ImClone Investigational Site
Tallinn, Estonia, 10138
ImClone Investigational Site
Tallinn, Estonia, 13419
France
ImClone Investigational Site
Besancon, France, 25030
ImClone Investigational Site
Brest, France, 29609
ImClone Investigational Site
Clermont-Ferrand, France, 63003
ImClone Investigational Site
Marseille, France, 13385
ImClone Investigational Site
Montbeliard, France, 25200
ImClone Investigational Site
Montpellier, France, 34298
ImClone Investigational Site
Paris, France, 75475
ImClone Investigational Site
Paris, France, 75013
ImClone Investigational Site
Paris, France, 75015
ImClone Investigational Site
Saint-Etienne, France, 42055
Germany
ImClone Investigational Site
Berlin, Germany, 13353
ImClone Investigational Site
Bielefeld, Germany, 33611
ImClone Investigational Site
Dresden, Germany, 01307
ImClone Investigational Site
Essen, Germany, 45136
ImClone Investigational Site
Frankfurt, Germany, 60596
ImClone Investigational Site
Hamburg, Germany, 22087
ImClone Investigational Site
Heidelberg, Germany, 69115
ImClone Investigational Site
Leipzig, Germany, 04103
ImClone Investigational Site
Mainz, Germany, 55131
ImClone Investigational Site
Munich, Germany, 81737
ImClone Investigational Site
Recklinghausen, Germany, 45657
ImClone Investigational Site
Tuebingen, Germany, 72076
Hungary
ImClone Investigational Site
Budapest, Hungary, 1125
ImClone Investigational Site
Gyula, Hungary, 5700
ImClone Investigational Site
Kaposvar, Hungary, 7400
ImClone Investigational Site
Pecs, Hungary, 7624
ImClone Investigational Site
Szekesfehervar, Hungary, 8000
Israel
ImClone Investigational Site
Beer Sheva, Israel, 84101
ImClone Investigational Site
Haifa, Israel, 31096
ImClone Investigational Site
Holon, Israel, 58100
ImClone Investigational Site
Jerusalem, Israel, 91120
ImClone Investigational Site
Petah Tikva, Israel, 49100
ImClone Investigational Site
Tel Hashomer, Israel, 52661
ImClone Investigational Site
Tel-Aviv, Israel, 64239
Italy
ImClone Investigational Site
Ancona, Italy, 60100
ImClone Investigational Site
Bari, Italy, 70126
ImClone Investigational Site
Bergamo, Italy, 24125
ImClone Investigational Site
Catania, Italy, 95122
ImClone Investigational Site
Genova, Italy, 16132
ImClone Investigational Site
Milano, Italy, 20121
ImClone Investigational Site
Padova, Italy, 35128
ImClone Investigational Site
Pisa, Italy, 56126
ImClone Investigational Site
Torino, Italy, 10100
Japan
ImClone Investigational Site
Aichi, Japan, 464
ImClone Investigational Site
Chiba, Japan, 277 8577
ImClone Investigational Site
Ehime, Japan, 790-0007
ImClone Investigational Site
Fukuoka, Japan, 811-1395
ImClone Investigational Site
Hokkaido, Japan, 060-0814
ImClone Investigational Site
Kochi, Japan, 781-8555
ImClone Investigational Site
Oita, Japan, 8795593
ImClone Investigational Site
Osaka, Japan, 569-8686
ImClone Investigational Site
Osaka-Pref, Japan, 589
ImClone Investigational Site
Saitama, Japan, 362-0806
ImClone Investigational Site
Shizuoka, Japan, 411-8777
ImClone Investigational Site
Tochigi, Japan, 320-0834
ImClone Investigational Site
Tokyo, Japan, 181-8611
Korea, Republic of
ImClone Investigational Site
Incheon, Korea, Republic of, 405-760
ImClone Investigational Site
Seongnam-Si, Korea, Republic of, 463-707
ImClone Investigational Site
Seoul, Korea, Republic of, 110-744
ImClone Investigational Site
Suwon, Korea, Republic of, 443-721
ImClone Investigational Site
Suwon-City, Korea, Republic of, 442-723
Lithuania
ImClone Investigational Site
Kaunas, Lithuania, LT-50009
ImClone Investigational Site
Klaipeda, Lithuania, LT-92288
Mexico
ImClone Investigational Site
Juchitan, Mexico, 70000
ImClone Investigational Site
Nuevo Leon, Mexico, 64060
Poland
ImClone Investigational Site
Brzozow, Poland, 36-200
ImClone Investigational Site
Bydgoszcz, Poland, 85-769
ImClone Investigational Site
Gdansk, Poland, 80-210
ImClone Investigational Site
Lodz, Poland, 93-509
ImClone Investigational Site
Lublin, Poland, 20-090
ImClone Investigational Site
Poznan, Poland, 61- 485
ImClone Investigational Site
Warsaw, Poland, 02-781
Portugal
ImClone Investigational Site
Aveiro, Portugal, 3814-501
ImClone Investigational Site
Coimbra, Portugal, 3001-651
ImClone Investigational Site
Evora, Portugal, 7000-811
ImClone Investigational Site
Porto, Portugal, 4202-451
ImClone Investigational Site
Santa Maria Da Feira, Portugal, 4520-211
Romania
ImClone Investigational Site
Baia Mare, Romania, 430031
ImClone Investigational Site
Bucharest, Romania
ImClone Investigational Site
Iasi, Romania, 700106
ImClone Investigational Site
Targu Mures, Romania, 540072
Russian Federation
ImClone Investigational Site
Krasnodar, Russian Federation, 350040
ImClone Investigational Site
Moscow, Russian Federation, 115478
ImClone Investigational Site
Perm, Russian Federation, 614066
ImClone Investigational Site
Saint Petersburg, Russian Federation, 191025
ImClone Investigational Site
Ufa, Russian Federation, 450054
Singapore
ImClone Investigational Site
Singapore, Singapore, 258499
Spain
ImClone Investigational Site
Avila, Spain, 05004
ImClone Investigational Site
Burgos, Spain, 9005
ImClone Investigational Site
Jerez De La Frontera, Spain, 11407
ImClone Investigational Site
Madrid, Spain, 28041
ImClone Investigational Site
Majadahonda, Spain, 28222
ImClone Investigational Site
Palma De Mallorca, Spain, 07014
ImClone Investigational Site
Sabadell, Spain, 08208
ImClone Investigational Site
Sevilla, Spain, 41009
Taiwan
ImClone Investigational Site
Changhua, Taiwan, 500
ImClone Investigational Site
Kaohsiung, Taiwan, 833
ImClone Investigational Site
Liouying/Tainan, Taiwan, 736
ImClone Investigational Site
Taichung, Taiwan, 404
ImClone Investigational Site
Tainan, Taiwan, 70403
ImClone Investigational Site
Taipei, Taiwan, 112
United Kingdom
ImClone Investigational Site
Maidstone, Kent, United Kingdom, ME16 9QQ
ImClone Investigational Site
Guildford, Surrey, United Kingdom, GU2 7XX
ImClone Investigational Site
Sutton, Surrey, United Kingdom, SM2 5PT
ImClone Investigational Site
Wolverhampton, West Midlands, United Kingdom, WV10 0QP
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01170663     History of Changes
Other Study ID Numbers: 13894, I4T-IE-JVBE, CP12-0922, 2010-020426-18
Study First Received: July 21, 2010
Results First Received: July 1, 2014
Last Updated: July 1, 2014
Health Authority: Argentina: Ministry of Health
Australia: Department of Health and Ageing Therapeutic Goods Administration
Austria: Agency for Health and Food Safety
Belgium: Federal Agency for Medicinal Products and Health Products
Brazil: National Health Surveillance Agency
Bulgaria: Ministry of Health
Chile: Ministry of Health
Estonia: The State Agency of Medicine
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Paul-Ehrlich-Institut
Hong Kong: Department of Health
Hungary: National Institute of Pharmacy
Israel: Ministry of Health
Italy: Ministry of Health
Japan: Pharmaceuticals and Medical Devices Agency
Lithuania: State Medicine Control Agency - Ministry of Health
Mexico: Ministry of Health
Poland: Ministry of Health
Portugal: National Pharmacy and Medicines Institute
Romania: National Medicines Agency
Russia: Ministry of Health of the Russian Federation
Singapore: Health Sciences Authority
South Korea: Korea Food and Drug Administration (KFDA)
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Taiwan: Department of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Keywords provided by Eli Lilly and Company:
Metastatic Adenocarcinoma
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Additional relevant MeSH terms:
Adenocarcinoma
Stomach Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 26, 2014